Regeneron Terminates Ocular Therapeutix Collaboration to Develop a Sustained-Release Formulation of Aflibercept

Ocular Therapeutix announced that Regeneron has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021.

The collaboration with Regeneron was initially formed in 2016 for the development and commercialization of products containing Ocular Therapeutix’s sustained-release hydrogel technology in combination with Regeneron’s large molecule vascular endothelial growth factor (“VEGF”)-targeting compounds to address conditions of the eye. Under a 2020 amendment, Ocular Therapeutix and Regeneron’s efforts have focused on research and development of an extended-delivery formulation of aflibercept to be delivered to the suprachoroidal space for the treatment of retinal diseases.

“While we are sorry to see the collaboration end, we are very grateful for having had the chance to work with a company like Regeneron and a molecule like aflibercept,” Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, said in a company news release. “Most importantly, we learned a great deal about how to formulate our proprietary hydrogel with monoclonal antibodies and to administer them to the suprachoroidal space. This work could become a valuable strategic driver for our future pipeline. We emerge from this collaboration with even more confidence in the versatility of our hydrogel platform and its utility in a route of administration which could become a safe and effective way to delivery medicine to the back of the eye.”